Subcutaneous Keytruda represents Merck’s solution to expand access to the popular PD-1 inhibitor and preserve some of its revenue as the original intravenous infusion version is expected to lose ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday ... which would become effective on January 1, 2028. The company said in a regulatory filing it expects U.S. sales of ...

Germany’s Merck MRK-2.82%decrease; red down pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-3.57%decrease; red down pointing ...

Merck is guiding for full-year sales between $64.1 billion to $65.6 billion, representing a range from a 0.2% decline to a 2.2% increase, compared to 2024. The silver lining here is the stronger ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

At Holdings Channel, we have reviewed the latest batch of the 27 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 15 of these ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best undervalued stocks. How Will Tariffs Affect the Market? On March 5th, BBC reported ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...